BIOMIND LABS INC. (3XI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIOMIND LABS INC. (3XI) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.70K ≈ $-45.24K USD) by net assets (€-1.56 Million ≈ $-1.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 3XI stock market capitalisation for the company's overall valuation and market capitalisation.
BIOMIND LABS INC. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how BIOMIND LABS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BIOMIND LABS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOMIND LABS INC. ranked by their cash flow conversion efficiency. Explore BIOMIND LABS INC. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Gulf Energy Ltd
AU:GGE
|
-0.003x |
|
Madhucon Projects Limited
NSE:MADHUCON
|
-0.150x |
|
Axilion Smart Mobility Ltd
TA:AILN
|
-0.914x |
|
Bluelinea SA
PA:ALBLU
|
-0.615x |
|
N2OFF Inc
NASDAQ:NITO
|
-0.089x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
Expion360 Inc
NASDAQ:XPON
|
-0.307x |
|
WestKam Gold Corp
V:WKG
|
0.023x |
Annual Cash Flow Conversion Efficiency for BIOMIND LABS INC. (2021–2024)
The table below shows the annual cash flow conversion efficiency of BIOMIND LABS INC. from 2021 to 2024. View BIOMIND LABS INC. (3XI) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.30 Million ≈ $-1.52 Million |
€-354.43K ≈ $-414.36K |
0.273x | -49.03% |
| 2023-12-31 | €-1.43 Million ≈ $-1.67 Million |
€-765.93K ≈ $-895.45K |
0.535x | -93.84% |
| 2022-12-31 | €-247.66K ≈ $-289.54K |
€-2.15 Million ≈ $-2.51 Million |
8.685x | +997.29% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€-2.12 Million ≈ $-2.48 Million |
-0.968x | -- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more